PO.PS01.12 · 人群科学
无论临床指征如何,良性前列腺活检中前列腺内炎症和调节性T细胞标志物FoxP3均随年龄增加:前列腺癌预防试验(PCPT)的安慰剂组
Intraprostatic inflammation and FoxP3, a marker of Regulatory T cells, increase with age in benign prostate biopsies irrespective of clinical indication: placebo arm of the Prostate Cancer Prevention Trial (PCPT)
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:前列腺内炎症被怀疑参与前列腺癌的发病机制。前列腺癌在实体癌中发病率随年龄上升最为陡峭,而炎症被认为随年龄增加。但前列腺组织通常仅从有临床指征的男性中获取,例如血浆前列腺特异性抗原(PSA)升高。鉴于PSA浓度随年龄增加而促使活检,年龄与炎症之间的关联可能存在偏倚。因此,我们使用了无论指征如何均采集的良性前列腺组织,以评估年龄与前列腺内炎症和免疫细胞丰度之间的关联。
方法:我们在PCPT安慰剂组的男性子集中进行了横断面分析。使用来自第7年方案规定的研究结束时前列腺活检的活检针芯(平均4个)切片,我们目视评估了炎症的存在和范围,并使用评分(0:无 - 4:广泛)对CD4(CD4+ T细胞)、CD8(CD8+ T细胞)、CD68(巨噬细胞)、FoxP3(调节性T细胞)和c-KIT(肥大细胞)的免疫组织化学染色进行了量化。评分按每位男性的针芯总数加权。使用逻辑回归估计年龄(连续或四分位数)与炎症指标(任一针芯有炎症 vs 无;全部或部分针芯有炎症 vs 无;平均组织炎症百分比≥3% 或 <3% vs 0%)之间的关联。使用线性回归估计年龄与免疫细胞标志物评分(连续)之间的关联。估计值针对种族、BMI、吸烟、体力活动、教育、糖尿病、他汀类药物使用和阿司匹林使用进行了校正。
结果:受试者(N=357)在活检时年龄为62至85岁(中位数70,IQR 65-74)。较大年龄与炎症的存在相关[年龄Q4 vs Q1:OR, 2.3;95% CI, 1.1-4.9,年龄间p趋势, 0.003]。与部分针芯[Q4 OR, 2.1;95% CI, 1.0-4.3]或全部针芯有炎症[Q4 OR, 7.8;95% CI, 2.0-30.6]也观察到正相关。年龄还与≥3%平均组织有炎症相关[Q4 OR, 2.6;95% CI, 1.2-6.0,p趋势, 0.006]。年龄与FoxP3评分呈正相关[p值, 0.01],但与任何其他免疫细胞标志物均无关联。排除PSA>4 ng/mL、诊断为前列腺癌或接受因病活检的男性后,关联略有减弱。
结论:无论指征如何进行的活检中,年龄与前列腺内炎症的存在和范围增加相关。与循环中的发现一致,前列腺活检中调节性T细胞的患病率随年龄增加。这些发现可能有助于阐明由炎症介导的年龄增加与前列腺癌之间的病因通路。资助:P50 DK082998、U01 CA182883、UG1CA189974、T32 CA09314、R01 CA255349、DOD。
查看英文原文 English abstract
Background : Intraprostatic inflammation is suspected to contribute to prostate cancer pathogenesis. Prostate cancer has the steepest age-related rise in incidence in solid cancers, and inflammation is thought to increase with age. But prostate tissue is typically obtained only from men with clinical indications, e.g., elevated plasma prostate-specific antigen (PSA). Associations between age and inflammation could be biased, given that PSA concentration increases with age, prompting biopsy. Thus, we used benign prostate tissue collected irrespective of indication to assess the association between age and intraprostatic inflammation and abundance of immune cells.
Methods : We performed a cross-sectional analysis in a subset of men of the PCPT placebo arm. Using slides containing biopsy cores (mean 4) from protocol-prompted end-of-study prostate biopsies at Year 7, we visually assessed the presence and extent of inflammation and quantified immunohistochemistry staining for CD4 (CD4+ T cells), CD8 (CD8+ T cells), CD68 (macrophages), FoxP3 (T regulatory cells), and c-KIT (mast cells) using a score (0: none - 4: extensive). Scores were weighted by total number of cores per man. Associations between age (continuous or quartiles) and inflammation measures (any core inflamed vs none; all or some cores inflamed vs none; mean percent tissue inflamed ≥3% or <3% vs 0%) were estimated using logistic regression. Associations between age and immune cell marker scores (continuous) were estimated using linear regression. Estimates were adjusted for race, BMI, smoking, physical activity, education, diabetes, statin use, and aspirin use.
Results : Participants (N=357) were 62 to 85 years of age at biopsy (median 70, IQR 65-74). Older age was associated with presence of inflammation [Q4 of age vs Q1: OR, 2.3; 95% CI, 1.1-4.9, p-trend across age, 0.003]. Positive associations were also observed with having some [Q4 OR, 2.1; 95% CI, 1.0-4.3] or all cores inflamed [Q4 OR, 7.8; 95% CI, 2.0-30.6]. Age was also associated with having ≥3% mean tissue with inflammation [Q4 OR, 2.6; 95% CI, 1.2-6.0, p-trend, 0.006]. Age was positively associated with FoxP3 score [p-value, 0.01], but not with any other immune cell markers. Associations were slightly attenuated when excluding men with PSA >4 ng/mL, diagnosed with prostate cancer, or who received for-cause biopsy.
Conclusion : Age is associated with increasing presence and extent of intraprostatic inflammation in biopsies taken irrespective of indication. Consistent with findings in circulation, prevalence of T regulatory cells in prostate biopsies increased with age. Findings may inform the etiologic pathway, mediated by inflammation, between increasing age and prostate cancer. Funding: P50 DK082998, U01 CA182883, UG1CA189974, T32 CA09314, R01 CA255349, DOD.
利益披露 Disclosure
Z. Lin,
AstraZeneca Employment.
L. M. Hurwitz, None..
I. Kulac, None..
B. Gumuskaya, None..
J. A. Baena-Del Valle, None..
I. Benedetti Padron, None..
K. B. Arnold, None..
M. Lucia, None..
I. M. Thompson, None.
C. G. Drake,
Johnson & Johnson Employment.
W. B. Isaacs, None..
W. G. Nelson, None..
C. M. Heaphy, None..
A. K. Meeker, None.
A. M. De Marzo,
AIRA Matrix ).
E. A. Platz, None.